Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02648347
Registration number
NCT02648347
Ethics application status
Date submitted
4/01/2016
Date registered
7/01/2016
Date last updated
27/06/2022
Titles & IDs
Public title
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Query!
Scientific title
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)
Query!
Secondary ID [1]
0
0
2015-004265-81
Query!
Secondary ID [2]
0
0
AKB-6548-CI-0014
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Anemia
0
0
Query!
Non-Dialysis-Dependent Chronic Kidney Disease
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Blood
0
0
0
0
Query!
Anaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Vadadustat
Treatment: Drugs - Darbepoetin alfa
Experimental: Vadadustat -
Active Comparator: Darbepoetin alfa -
Treatment: Drugs: Vadadustat
Oral dose administered once daily for =36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Treatment: Drugs: Darbepoetin alfa
Subcutaneous or intravenous dose administered for =36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Query!
Assessment method [1]
0
0
The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline Hb concentration (<9.5 versus =9.5 grams per deciliter [g/dL]), geographic region (United States [US] versus European Union [EU] versus Rest of World [ROW]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 [no CHF] or I versus II or III) as covariates.
Query!
Timepoint [1]
0
0
Baseline; Weeks 24 to 36
Query!
Primary outcome [2]
0
0
Median Time to First Major Adverse Cardiovascular Event (MACE)
Query!
Assessment method [2]
0
0
MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0014 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [2]
0
0
Up to Week 208
Query!
Secondary outcome [1]
0
0
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
Query!
Assessment method [1]
0
0
The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline Hb concentration (<9.5 versus =9.5 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 [no CHF] or I versus II or III) as covariates.
Query!
Timepoint [1]
0
0
Baseline; Weeks 40 to 52
Query!
Secondary outcome [2]
0
0
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
Query!
Assessment method [2]
0
0
MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0014 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [2]
0
0
Up to Week 208
Query!
Secondary outcome [3]
0
0
Median Time to First Cardiovascular MACE
Query!
Assessment method [3]
0
0
MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0014 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [3]
0
0
Up to Week 208
Query!
Secondary outcome [4]
0
0
Median Time to First Cardiovascular Death
Query!
Assessment method [4]
0
0
Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0014 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [4]
0
0
Up to Week 208
Query!
Secondary outcome [5]
0
0
Median Time to First All-cause Mortality
Query!
Assessment method [5]
0
0
Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0014 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.
Query!
Timepoint [5]
0
0
Up to Week 208
Query!
Eligibility
Key inclusion criteria
- =18 years of age
- Diagnosis of chronic kidney disease (CKD) with an estimated glomerular filtration rate
=60 milliliters per minute per 1.73 square meter (mL/min/1.73 m^2) at Screening and
not expected to start dialysis within 6 months of Screening
- Mean Screening hemoglobin <10.0 grams per deciliter (g/dL)
- Serum ferritin =100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT)
=20% during Screening
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Anemia due to a cause other than CKD or participants with active bleeding or recent
blood loss
- Red blood cell transfusion within 8 weeks prior to randomization.
- Any erythropoietic stimulating agent within 8 weeks prior to randomization
- Uncontrolled hypertension
- Severe heart failure at Screening (New York Heart Association Class IV)
- Acute coronary syndrome (hospitalization for unstable angina or myocardial
infarction), surgical or percutaneous intervention for coronary, cerebrovascular, or
peripheral artery disease (aortic or lower extremity), surgical or percutaneous
valvular replacement or repair, sustained ventricular tachycardia, hospitalization for
heart failure, or stroke within 12 weeks prior to or during Screening
- Hypersensitivity to Darbepoetin or Vadadustat or to any of their excipients
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1751
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Research Site - Liverpool
Query!
Recruitment hospital [3]
0
0
Research Site - Cairns
Query!
Recruitment hospital [4]
0
0
Research Site - Gold Coast
Query!
Recruitment hospital [5]
0
0
Research Site - Herston
Query!
Recruitment hospital [6]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [7]
0
0
Research Site - Bedford Park
Query!
Recruitment hospital [8]
0
0
Research Site - Box Hill
Query!
Recruitment hospital [9]
0
0
Research Site - Nedlands
Query!
Recruitment hospital [10]
0
0
Research Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [4]
0
0
9726 - Gold Coast
Query!
Recruitment postcode(s) [5]
0
0
4006 - Herston
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [8]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [9]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [10]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Montana
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nebraska
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nevada
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Hampshire
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Jersey
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Mexico
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New York
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
North Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Ohio
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Oregon
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Pennsylvania
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Rhode Island
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Tennessee
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Texas
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Utah
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Virginia
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Washington
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Wisconsin
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
Buenos Aires
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Mendoza
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Santa Fe
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
Tucuman
Query!
Country [42]
0
0
Argentina
Query!
State/province [42]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [43]
0
0
Argentina
Query!
State/province [43]
0
0
Cordoba
Query!
Country [44]
0
0
Argentina
Query!
State/province [44]
0
0
Corrientes
Query!
Country [45]
0
0
Argentina
Query!
State/province [45]
0
0
Salta
Query!
Country [46]
0
0
Argentina
Query!
State/province [46]
0
0
San Luis
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Bahia
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Ceará
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Espírito Santo
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
Minas Gerais
Query!
Country [51]
0
0
Brazil
Query!
State/province [51]
0
0
Paraná
Query!
Country [52]
0
0
Brazil
Query!
State/province [52]
0
0
Rio Do Janeiro
Query!
Country [53]
0
0
Brazil
Query!
State/province [53]
0
0
Rio Grande Do Sul
Query!
Country [54]
0
0
Brazil
Query!
State/province [54]
0
0
Santa Catarina
Query!
Country [55]
0
0
Brazil
Query!
State/province [55]
0
0
Sao Paulo
Query!
Country [56]
0
0
Bulgaria
Query!
State/province [56]
0
0
Dobrich
Query!
Country [57]
0
0
Bulgaria
Query!
State/province [57]
0
0
Lom
Query!
Country [58]
0
0
Bulgaria
Query!
State/province [58]
0
0
Silistra
Query!
Country [59]
0
0
Bulgaria
Query!
State/province [59]
0
0
Sliven
Query!
Country [60]
0
0
Bulgaria
Query!
State/province [60]
0
0
Smolyan
Query!
Country [61]
0
0
Bulgaria
Query!
State/province [61]
0
0
Sofia
Query!
Country [62]
0
0
Bulgaria
Query!
State/province [62]
0
0
Stara Zagora
Query!
Country [63]
0
0
Bulgaria
Query!
State/province [63]
0
0
Varna
Query!
Country [64]
0
0
Bulgaria
Query!
State/province [64]
0
0
Veliko Tarnovo
Query!
Country [65]
0
0
Bulgaria
Query!
State/province [65]
0
0
Vidin
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Val d'Oise
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Baja
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Balatonfured
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Budapest
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Debrecen
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Hodmezovasarhely
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Kalocsa
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Kaposvar
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Kecskemet
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Kistarcsa
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Nyiregyhaza
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Pecs
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Szeged
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Szigetvar
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Ashkelon
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Haifa
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Nahariya
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Ramat Gan
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Rishon Lezion
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Caserta
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Foggia
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Bari
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Bergamo
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Cremona
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Genova
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Lecco
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Milano
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Napoli
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Parma
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Pavia
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Roma
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Siena
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Gyeonggi-do
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Busan
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Daegu
Query!
Country [101]
0
0
Korea, Republic of
Query!
State/province [101]
0
0
Seoul
Query!
Country [102]
0
0
Malaysia
Query!
State/province [102]
0
0
Kelantan
Query!
Country [103]
0
0
Malaysia
Query!
State/province [103]
0
0
Pahang
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
Distrito Federal
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Guerrero
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Hidalgo
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Jalisco
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Michoacán
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Nuevo León
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Queretaro
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
Sinaloa
Query!
Country [112]
0
0
Mexico
Query!
State/province [112]
0
0
Chihuahua
Query!
Country [113]
0
0
Mexico
Query!
State/province [113]
0
0
Durango
Query!
Country [114]
0
0
Mexico
Query!
State/province [114]
0
0
Veracruz
Query!
Country [115]
0
0
New Zealand
Query!
State/province [115]
0
0
Hamilton
Query!
Country [116]
0
0
New Zealand
Query!
State/province [116]
0
0
New Plymouth
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Lodz
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Nowa Sol
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Warszawa
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Wroclaw
Query!
Country [121]
0
0
Puerto Rico
Query!
State/province [121]
0
0
Caguas
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
Kazan
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Kemerovo
Query!
Country [124]
0
0
Russian Federation
Query!
State/province [124]
0
0
Krasnoyarsk
Query!
Country [125]
0
0
Russian Federation
Query!
State/province [125]
0
0
Moscow
Query!
Country [126]
0
0
Russian Federation
Query!
State/province [126]
0
0
Nizhniy Novgorod
Query!
Country [127]
0
0
Russian Federation
Query!
State/province [127]
0
0
Novosibirsk
Query!
Country [128]
0
0
Russian Federation
Query!
State/province [128]
0
0
Petrozavodsk
Query!
Country [129]
0
0
Russian Federation
Query!
State/province [129]
0
0
Pushkin
Query!
Country [130]
0
0
Russian Federation
Query!
State/province [130]
0
0
Saint-Petersburg
Query!
Country [131]
0
0
Russian Federation
Query!
State/province [131]
0
0
Tomsk
Query!
Country [132]
0
0
Russian Federation
Query!
State/province [132]
0
0
Tosno
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
Yaroslavl
Query!
Country [134]
0
0
South Africa
Query!
State/province [134]
0
0
Eastern Cape
Query!
Country [135]
0
0
South Africa
Query!
State/province [135]
0
0
Free State
Query!
Country [136]
0
0
South Africa
Query!
State/province [136]
0
0
Gauteng
Query!
Country [137]
0
0
South Africa
Query!
State/province [137]
0
0
KwaZulu-Natal
Query!
Country [138]
0
0
South Africa
Query!
State/province [138]
0
0
Western Cape
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Alicante
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Baleares
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Barcelona
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Málaga
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
Almeria
Query!
Country [144]
0
0
Spain
Query!
State/province [144]
0
0
Badajoz
Query!
Country [145]
0
0
Spain
Query!
State/province [145]
0
0
Madrid
Query!
Country [146]
0
0
Spain
Query!
State/province [146]
0
0
Sevilla
Query!
Country [147]
0
0
Spain
Query!
State/province [147]
0
0
Valencia
Query!
Country [148]
0
0
Ukraine
Query!
State/province [148]
0
0
Dnipro
Query!
Country [149]
0
0
Ukraine
Query!
State/province [149]
0
0
Ivano-Frankivsk
Query!
Country [150]
0
0
Ukraine
Query!
State/province [150]
0
0
Kharkiv
Query!
Country [151]
0
0
Ukraine
Query!
State/province [151]
0
0
Kropyvnytskyi
Query!
Country [152]
0
0
Ukraine
Query!
State/province [152]
0
0
Kyiv
Query!
Country [153]
0
0
Ukraine
Query!
State/province [153]
0
0
Lviv
Query!
Country [154]
0
0
Ukraine
Query!
State/province [154]
0
0
Mykolaiv
Query!
Country [155]
0
0
Ukraine
Query!
State/province [155]
0
0
Odesa
Query!
Country [156]
0
0
Ukraine
Query!
State/province [156]
0
0
Vinnytsia
Query!
Country [157]
0
0
Ukraine
Query!
State/province [157]
0
0
Zaporizhzhia
Query!
Country [158]
0
0
Ukraine
Query!
State/province [158]
0
0
Zhytomyr
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Grampian Region
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Greater London
Query!
Country [161]
0
0
United Kingdom
Query!
State/province [161]
0
0
Greater Manchester
Query!
Country [162]
0
0
United Kingdom
Query!
State/province [162]
0
0
Hertfordshire
Query!
Country [163]
0
0
United Kingdom
Query!
State/province [163]
0
0
Leicestershire
Query!
Country [164]
0
0
United Kingdom
Query!
State/province [164]
0
0
South Yorkshire
Query!
Country [165]
0
0
United Kingdom
Query!
State/province [165]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Akebia Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of
anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic
Kidney Disease (NDD-CKD)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02648347
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Chief Medical Officer
Query!
Address
0
0
Akebia Therapeutics Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02648347
Download to PDF